Investor Presentation

December 2014

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause VYCOR MEDICAL's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in VYCOR'S SEC filings. All forward-looking statements attributable to VYCOR herein are expressly qualified in their entirety by the abovementioned cautionary statement. VYCOR disclaims any obligation to update forward-looking statements contained in this estimate , except as may be required by law. The recipient acknowledges that Vycor Medical, Inc. is a publicly traded company. Recipient acknowledges that any confidential information constituting material nonpublic information that Vycor Medical, Inc. provides to the recipient is being provided to the recipient in reliance upon the agreement that the information will remain confidential. By accepting this material, the recipient acknowledges that it is aware of the applicable requirements of the federal securities laws relating to material non-public information and trading in securities of Vycor Medical, Inc.

2

• Two distinct businesses – both with “game changing” products

• Devices are FDA-cleared, development risk now off the table

• Address significant markets – NovaVision ~$4bn in the US/Europe, up to ~$13bn globally – Vycor $700m globally

• Limited competition – NovaVision VRT only FDA cleared therapy targeted at vision loss from neurological brain damage such as stroke

• Significant barriers to entry:

Robust patent portfolio; 42 granted and 13 pending patents

Significant published clinical data underpinning technologies

Established international footprint

Strong new product pipeline

3

4

ViewSite NovaVision

Lead product ViewSite Brain Access System (VBAS) is a revolutionary neurosurgical device used to gain access to a target within the brain e.g. tumor VBAS parts the brain tissue (retraction) and creates a working channel

Leader in the field of vision rehabilitation for neurological brain damage e.g. stroke. Suite of complementary therapies: • Vision Restoration Therapy (VRT)

targeted at restoration of lost vision • NeuroEyeCoach re-trains scanning and

makes the best of remaining vision

5

6

Has a Suite of Complementary Therapies Address Patients with Visual Field Deficits Resulting from Stroke, Brain Injury or Other Neurological Trauma

Visible object

7

• ~8 million Stroke survivors in US. 480,000+ new stroke survivors a year

• 28% of Stroke victims suffer from visual disorders

• 20% experience permanent visual field deficits

Significant Target Market Est. US/Europe $4bn, Globally up to $13bn

Vision Loss from Stroke and TBI is a Big Unaddressed Issue

Visual Field Deficit is a Major Inhibitor to Daily Living 8

• The current pillar therapy areas are:

– Speech

– Physical

– Occupational

• NovaVision focuses on the critical missing therapy

Occu

patio

nal

Key Therapies

Vis

ion

• VRT is the only FDA cleared therapy (510k) for restoration of vision loss from neurological damage

• A light based prescription stimulation therapy – “at home”

• Clinically proven to restore lost vision

• 20 clinical studies/papers approximately 70% of patients benefit

• Substantial IP portfolio: 33 granted/issued, 5 pending

• No clinically supported alternative

• No other real competitors – Sight Science the largest, purchased in 2012

9

Pre-VRT Post-VRT

“My vision began coming back after the first month of therapy…I passed my driving test, can read normally, and enjoy driving my boat on the lake…my life is back to

normal.” – Stroke survivor and VRT patient

Illustration of the Impact of the Improvement in a Patient’s Visual Field and Consequently on their Ability to Get Around Unassisted

10

Ensure broad benefit from NovaVision therapies and not only 70% from VRT

Drive down cost of delivery inherent with “hardware centric” business model and processing costs to largely remove pricing barriers

Create a scalable business model capable of addressing the size of the mark

11

Prototypes historically delivered on a custom

designed piece of hardware

Development Work Now Complete

• Broaden benefit to all patients not only 70% provided by VRT through the introduction of new therapy in patients overall therapy regime

• Scientific Advisory Board recommended introduction of saccadic eye training program to complement VRT:

Scientifically supported to benefit patients

Previously only available on a large board requiring direct physician supervision

NeuroEyeCoach developed - First Commercially available computer-based eye movement therapy available at home

Supported by four decades of research and developed by Josef Zihl world leader in the space

12

• Significant Physician and Rehab Center interest led to the development of two new Professional NeuroEyeCoach models:

Both programs now complete

Professional Center Program being trialed in largest rehab center in US

NovaVision has already commenced a three-center patient trial for NeuroEyeCoach in Germany, Austria and Italy

Preliminary data being presented at 5th Annual Conference of the DGNR (German Society of Neurological Rehabilitation) in early December

13

14

• Web deliverable VRT development now completed

• Therapy suite of VRT and NEC commercially available first quarter 2015

Broader benefit to patients

Web delivery ensures scalability

Elimination of previously required hardware enables significant reduction in pricing: (~$3,000 today for VRT to approx $900 for both VRT and NeuroEyeCoach)

• Most Stroke patients visit a rehabilitation center at some point in time

• Diagnostic component already part of VRT

• Rehab center derives financial benefit and improves patient outcomes

• Eligible candidates will then be referred for VRT to NovaVision

• Will also generate revenues from licensing and installation of devices

15

NovaVision has received approval from HealthSouth to make available its VRT diagnostic to its 100+ hospital network, following a trial

“It is the ideal system for providing deep brain access through a smaller incision.”

-Neurosurgeon Quote

16

Old Blade/Ribbon Retractor Technology Evenly disperses and reduces pressure

More accurate target access, no target shifting

Superior field of view, clear working channel

Less invasive: requires smaller opening

IGS and inter-operative MRI compatible

No reported injuries with VBAS. 5-10% reported injury rate with blade

17

VBAS Next Generation Technology

Surgeon Discussions Indicate that VBAS Offers Savings for Hospitals:

Surgeon feedback indicates that VBAS can reduce the operating time

Shorten discharge times

Reduced use of consumables during Operation

= Potential Savings of Thousands of Dollars Per Procedure 18

“Her case would have been inoperable via a traditional surgery, because she was taking Avastin®, which delays surgical wound healing. The VBAS’ minimally invasive nature enabled the surgeon to gain access to the target through only a 3cm incision. The patient was discharged uneventfully and there were no issues regarding her wound” – Daniel Prevedello, MD, Director of the Minimally Invasive Cranial Surgery Program at the Ohio State University “We would not have attempted this without this technology. It’s very exciting” – Bullet fragment removal: Narayan Sundaresan, MD. Chief Neurosurgeon, Lincoln Hospital and Prof. At Mt, Sinai, NYC

Previously Inoperable…Now Operable

Product Has Been Used in Previously Inoperable Procedures - Thus Saving Lives 19

Drive US Market Penetration

Increase Focus on International Expansion

Secure More Clinical and Scientific Data

Focus on New Product Development

Management’s 4 Pronged Strategy to Drive Revenue and Shareholder Value

20

Progress Year to Date:

• Well defined target market of 3,500 neurosurgeons being aggressively marketed to directly with clinical data

• VBAS continues to gain traction with neurosurgeons: VBAS approved in 23 hospitals year to date bringing total to >170

• Strong pipeline of hospitals going through the approval process

• Strengthening distributor network with 4 new distributors added YTD

• Broadening the product’s usage beyond “deep and difficult procedures” – new “VBAS Brain Atlas” being worked on by Weill Cornell

• Strategic partnerships being evaluated to joint-market and co-sponsor teaching events

21

Progress Year to Date:

• Systematic focus on International Markets

• Target countries where it has patent protection and/or clear regulatory path

• Utilize distributors with experience in neurosurgical devices

• Entered into distribution or evaluation agreements with Brazil, France, India, Russia, South Africa, Sri Lanka and Taiwan

22

• Strong Support from leading neurosurgeons at Weill Cornell Medical Center:

Submitted two peer reviewed papers using Vycor’s VBAS bringing total to 7 peer reviewed/published studies

Presented their work with the VBAS in Xian China, Prague, Paris and most recently the CNS in Boston

Pipeline of new studies anticipated culminating in a published “VBAS Atlas of the Brain” which should be completed next year

• Ohio State University, Minimally Invasive Cranial Surgery Program Animal Study now complete with publication anticipated next year

Progress Year to Date:

Significant New Clinical Data Anticipated 23

Progress Year to Date:

• Two smaller VBAS devices now going through manufacturing process in Asia

• Finalization of design and testing on New IGS compatible devices. Co Marketing and Co Promotion Agreement being explored. Broad compatibility strategy being adopted.

24

IGS Design IGS Prototype

Publicly Traded on OTCQB, VYCO

Current share price (11/24/14) $2.18

Shares Ent. Value (1)

Common 10.9m $21.6m

Common and Preferred 12.0m $24.0m

Fully diluted (for options and warrants) 17.9m $27.7m

Cash Balance 9/30/14 $2.5m

Operating Cash Burn Q1-3 2014 (2) $1.1m

25

(1) Enterprise Value is market cap less cash net of debt; fully diluted enterprise value adjusts for warrant exercise proceeds (2) Non-GAAP operating loss for 9 months Sep 30, 2014, before: amortization of acquired IP; stock compensation; offering costs; losses on

debt exchange and warrant extension

Peter Zachariou - Chief Executive Officer David Cantor- President

Management Presenting

Corporate Headquarters

6401 Congress Avenue Suite 140 Boca Raton, FL. 33487

www.vycormedical.com

www.vycorvbas.com

www.novavision.com

www.novavisionvrt.com

www.neuroeyecoach.com

www.sightscience.com

German Office

Klausenerstr. 12 39112 Magdeburg, Germany

UK Office

Life Science Innovation Building Cornhill Road Foresterhill, Aberdeen AB24 3FX, Scotland, UK

26

Our Websites

Supplemental Group Information

27

Name Title Experience

Peter

Zachariou

CEO &

Director

Extensive operating experience over range of manufacturing businesses

Active investor in variety of companies and industries, both public and private,

specializing in capital formation/raising and development companies

David

Cantor President

22 years experience of Investing in, raising money for and providing strategic advice to

growth companies across a broad range of sectors

Investment Banking (Citigroup, Donaldson, Lufkin & Jenrette, Lehman Brothers)

Adrian

Liddell

Chairman

and CFO

Over 30 years of strategic, corporate and financial advisory and company investment

Private equity (Phoenix Equity Partners); Investment Banking (Citigroup, Donaldson,

Lufkin & Jenrette, Lehman Brothers)

Chartered Accountant

Steven

Girgenti Director

Pharmaceutical and healthcare executive with 45 years experience

Managing partner of Medi-Pharm consulting, providing strategic advice to healthcare

companies

Former President and CEO of DermWorx and former Chairman of Ogilvy Healthworld

Lowell

Rush Director

CEO of Direct Incite, Inc.

Former COO of Cosmetic Dermatology Inc.,CFO of Bijoux Terner and Little Switzerland,

and has held operational and financial roles at SunGlasses Hut, Burger King and Knight-

Ridder. CPA and MBA

Dr. Oscar

Bronsther Director

Clinical professor at George Washington Univ. and Director of Transplant Services at Kaiser Permanente Medical Group. Previously Associate Prof. at Univ of Rochester, Univ of

Pittsburg and Univ. of California San Diego

Pascale

Mangiardi Director President of Rougemont Management Services 28

Name Experience and Affiliations

Dr David Langer

Vycor

Director of Cerebrovascular Neurosurgery at St. Luke’s-Roosevelt, Beth-Israel and Long

Island College Hospitals (New York, NY)

Dr Konstantin Slavin

Vycor

University of Illinois at Chicago (Chicago, IL); Alexian Neuroscience Center (Elk Grove

Village, IL); Director of Illinois Gamma Knife Center

Dr Ezriel Kornel

Vycor

Director, Institute for Neurosciences at Northern Westchester Hospital Center (Mount

Kisco, NY); President-elect New York State Neurosurgical Society; Board of Directors,

Medical Liability Mutual Insurance; Director for Center Neurochiropractic Education

Prof. Arash Sahraie

NovaVision

Professor, Chair in Vision Sciences at Univ. of Aberdeen (UK); PhD in Optics and Visual

Science, City Univ. (London, UK); Founder of Sight Science Ltd

Alvaro Pascale-Leone,

MD/PhD

NovaVision

Professor of Neurology at Harvard Medical School; Director of Research, Cognitive

Neurology Unit, Beth Israel Deaconess Medical Center; MD/PhD Neurophysiology, Albert-

Ludwigs Univ (Germany); Former Medical Fellow National Institute of Health; Author 450+

Scientific papers as well as several books

Jason S. Barton, MD

NovaVision Professor of Neurology, Ophthalmology and Visual Sciences, University of British Columbia

Joseph Zihl, MD

NovaVision

Professor of Neuropsychology at Department of Psychology, Univ. of Munich (Germany),

Head of Neuropsychology Research Group at the Max Planck Institute of Psychology

Jose Romano, MD

NovaVision

Chief of Stroke Division and Professor of Neurology at the University of Miami Miller School of Medicine

29

30

• Each 1mm² of a nerve bundle carries up to 1 million nerve fibers

• Brain injury often affects an extensive network of connectivity

• Some networks in the brain are duplicated and some are not

• Improvements are probably related to “extensive redundancy” of

connectivity enabling usage of alternative routes following systematic stimulation

• fMRI shows increased activity when stimulated by VRT

Exact Mechanism of Neuroplasticity is Not Known: